These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Cheung CS; Wong AW; Lui A; Kertes PJ; Devenyi RG; Lam WC Ophthalmology; 2012 Aug; 119(8):1609-14. PubMed ID: 22480743 [TBL] [Abstract][Full Text] [Related]
4. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Artunay O; Yuzbasioglu E; Rasier R; Sengül A; Bahcecioglu H Eye (Lond); 2009 Dec; 23(12):2187-93. PubMed ID: 19218994 [TBL] [Abstract][Full Text] [Related]
5. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Shah CP; Garg SJ; Vander JF; Brown GC; Kaiser RS; Haller JA; Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087 [TBL] [Abstract][Full Text] [Related]
6. Endophthalmitis after resident-performed intravitreal bevacizumab injection. Falavarjani KG; Aghamirsalim M; Modarres M; Hadavandkhani A; Hashemi M; Parvaresh MM; Naseripour M; Samiy N Can J Ophthalmol; 2015 Feb; 50(1):33-6. PubMed ID: 25677280 [TBL] [Abstract][Full Text] [Related]
7. Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a single clinical center. Falavarjani KG; Modarres M; Hashemi M; Parvaresh MM; Naseripour M; Zare-Moghaddam A; Nekoozadeh S Retina; 2013 May; 33(5):971-4. PubMed ID: 23400076 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy. Lima LH; Zweifel SA; Engelbert M; Sorenson JA; Slakter JS; Cooney MJ; Klancnik JM; Yannuzzi LA; Freund KB Retina; 2009 Oct; 29(9):1213-7. PubMed ID: 19934815 [TBL] [Abstract][Full Text] [Related]
9. Endophthalmitis after intravitreal injection: the importance of viridans streptococci. Chen E; Lin MY; Cox J; Brown DM Retina; 2011 Sep; 31(8):1525-33. PubMed ID: 21878800 [TBL] [Abstract][Full Text] [Related]
10. Bilateral simultaneous intravitreal injections in the office setting. Bakri SJ; Risco M; Edwards AO; Pulido JS Am J Ophthalmol; 2009 Jul; 148(1):66-9.e1. PubMed ID: 19403114 [TBL] [Abstract][Full Text] [Related]
11. Safety study of 38,503 intravitreal ranibizumab injections performed mainly by physicians in training and nurses in a hospital setting. Hasler PW; Bloch SB; Villumsen J; Fuchs J; Lund-Andersen H; Larsen M Acta Ophthalmol; 2015 Mar; 93(2):122-5. PubMed ID: 25403735 [TBL] [Abstract][Full Text] [Related]
12. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Mason JO; White MF; Feist RM; Thomley ML; Albert MA; Persaud TO; Yunker JJ; Vail RS Retina; 2008 Apr; 28(4):564-7. PubMed ID: 18398358 [TBL] [Abstract][Full Text] [Related]
13. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Fintak DR; Shah GK; Blinder KJ; Regillo CD; Pollack J; Heier JS; Hollands H; Sharma S Retina; 2008; 28(10):1395-9. PubMed ID: 18827737 [TBL] [Abstract][Full Text] [Related]
14. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration]. Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687 [TBL] [Abstract][Full Text] [Related]